140 related articles for article (PubMed ID: 38841677)
1. The concentration of maternal sacubitril/valsartan transferred into human milk is negligible.
Falconi S; Okimi A; Wesley S; Sethi P; Datta P; Krutsch K
Front Public Health; 2024; 12():1389513. PubMed ID: 38841677
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination and pharmacokinetics study of valsartan, sacubitril and its major metabolite in human plasma, urine and peritoneal dialysis fluid in patients with end-stage renal disease by UPLC-MS/MS.
Jin Y; He Y; Di X; Fu L; Qi X; Liu R; Zheng L; Wang Y; Zhong H; Wang Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1208():123402. PubMed ID: 35930849
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
He Y; Jin Y; Xue H; Liu R; Zhang M; Liao R; Chen M; Zhou X; He X; Qin M; Li K; Zou H; Gan Y; Wang Z; Zheng L; Zhong H; Fu P
Nephrol Dial Transplant; 2023 Jul; 38(8):1880-1889. PubMed ID: 36787894
[TBL] [Abstract][Full Text] [Related]
5. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.
Yang Q; Cao P; Lv Y; Peng H; Zhai X
J Pharm Biomed Anal; 2024 Jan; 238():115829. PubMed ID: 37948774
[TBL] [Abstract][Full Text] [Related]
7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
8. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).
Ayalasomayajula S; Han Y; Langenickel T; Malcolm K; Zhou W; Hanna I; Alexander N; Natrillo A; Goswami B; Hinder M; Sunkara G
J Clin Pharm Ther; 2016 Aug; 41(4):424-31. PubMed ID: 27321165
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
10. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
11. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Norberg H; Bergdahl E; Lindmark K
Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
Pascual-Figal D; Wachter R; Senni M; Belohlavek J; Noè A; Carr D; Butylin D
ESC Heart Fail; 2018 Apr; 5(2):327-336. PubMed ID: 29239515
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril-valsartan vs ACE/ARB in pediatric heart failure: A retrospective cohort study.
Hale ZE; Prichett L; Jandu S; Ravekes W
J Heart Lung Transplant; 2024 May; 43(5):826-831. PubMed ID: 38705701
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan Off-Label Uses for Heart Failure.
Kido K; Colvin BM; Szymanski TW; Guglin M
J Card Fail; 2022 Jul; 28(7):1185-1201. PubMed ID: 35405341
[TBL] [Abstract][Full Text] [Related]
16. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
18. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
[TBL] [Abstract][Full Text] [Related]
20. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs.
Epperson CN; Jatlow PI; Czarkowski K; Anderson GM
Pediatrics; 2003 Nov; 112(5):e425. PubMed ID: 14595087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]